Drug Database
TE

teriparatide (Osteoform / Osteotide)

✓ Approved

Virchow Biotech · PTH1R · 重组蛋白

什么是 teriparatide?

teriparatide 是一种重组蛋白,由Virchow Biotech研发。该药已获批,用于治疗相关适应症,给药途径:Injectable (Others)、Subcutaneous Injection。

药物档案

商品名Osteoform, Osteotide
公司Virchow Biotech
药物类别重组蛋白
分子靶点PTH1R
给药途径Injectable (Others), Subcutaneous Injection
状态Approved

作用机制

分子靶点

teriparatide 作用于 1 个分子靶点:

PTH1Rparathyroid hormone 1 receptor (PTHR, EKNS)
需要更深入的分析?Noah AI 可解释复杂机制并与同类药物比较。

治疗适应症

teriparatide 针对 1 个适应症,涉及 1 个治疗领域。

治疗领域疾病/病症分期
Musculoskeletal and connective tissue disordersOsteoporosis✓ Approved

相关研究文献

PubMedCurrent osteoporosis reports2026-11-17

Osteoporosis Treatment in Lumbar Fusion: A Scoping Review.

Salman Samer G SG, Phadke Rohan A RA, Franco Adam S AS, Tummala Sri S et al.

Perioperative pharmacologic bone-health optimization is increasingly recommended before lumbar fusion, but the supporting evidence may not apply to short-segment degenerative fusion. This scoping review mapped how well treatment recommendations are supported in that population. Of 1,842 records screened, 145 underwent full-text review and 54 met inclusion criteria. Most high-level evidence pooled degenerative disease with adult spinal deformity and osteoporotic vertebral fracture without construct-specific analysis. In short-segment degenerative fusion, small teriparatide studies reported lower screw loosening and higher or earlier union, whereas a 1,040-patient registry found no reduction in operative nonunion with preoperative bisphosphonates. High-quality short-segment data for romosozumab and abaloparatide were absent, and timing and duration were inconsistent. Recommendations are supported by biologic rationale but limited by population mismatch. Teriparatide has the strongest degenerative-specific signal; evidence for bisphosphonates and newer agents is insufficient. Future trials should isolate 1- to 2-level degenerative fusion and prioritize cage subsidence, screw loosening, fusion, and reoperation.

PMID 43040140
阅读全文 →
PubMedClinical kidney journal2026-11-15

Hypocalcaemia and hospitalization after initiation of bone-modifying agents in dialysis patients.

Imaizumi Takahiro T, Nishibori Nobuhiro N, Okazaki Masaki M, Nagase Koya K et al.

Bone-modifying agents are associated with hypocalcaemia in dialysis patients, leading to serious adverse consequences. We examined factors associated with all-cause hospitalization, longitudinal serum calcium trajectories by medication class, and baseline predictors of hypocalcaemia in dialysis patients initiating bone-modifying agents. Using the JMDC hospital database, we identified dialysis patients newly prescribed bisphosphonates, denosumab, teriparatide, or romosozumab. Factors associated with all-cause hospitalization were examined using Cox regression. Serum calcium trajectories were assessed over 90 days before and after treatment initiation. Factors associated with hypocalcaemia (corrected calcium <8.0 mg/dl) within 90 days were analysed. Among 2020 patients on dialysis, 1057 (52.3%) received bisphosphonates; 693 (34.3%), denosumab; 136 (6.7%), teriparatide; and 134 (6.6%), romosozumab. Hospitalization occurred in 425 patients, and recent hospitalization and pretreatment lower corrected serum calcium levels were associated with hospitalization, with no significant differences across medications. Among 374 patients with laboratory data, post-treatment hypocalcaemia occurred in 99 (26.5%). Persistent reductions in serum calcium levels were observed after initiating denosumab or romosozumab. Adjusted odds ratios (OR) for post-treatment hypocalcaemia were 13.4 (6.90-26.1) for denosumab and 8.09 (2.20-29.8) for romosozumab. Pretreatment calcium and parathyroid hormone levels were associated with post-treatment hypocalcaemia [adjusted ORs: 0.29 (0.18, 0.49) and 1.59 (1.05, 2.39), respectively]. In dialysis patients, denosumab and romosozumab were associated with a higher risk of post-treatment hypocalcaemia than bisphosphonates, and pretreatment lower calcium was associated with hospitalization. Our findings highlight the importance of optimizing parathyroid hormone management and enhancing calcium monitoring when initiating bone-modifying agents.

PMID 43032270
阅读全文 →
PubMedTherapeutic advances in musculoskeletal disease2026-11-15

The paradox of osteoporosis in axial spondyloarthritis: Why antiresorptives may not be enough and anabolic therapy could be prioritized.

Ligocki Piotr P, Wojciechowski Rafał R, Żuchowski Paweł P, Dura-Kuczyńska Marta M et al.

Osteoporosis (OP) in radiographic axial spondyloarthritis (r-axSpA) exhibits a paradoxical mechanism. Chronic inflammation driven by pro-inflammatory cytokines (TNF-α, IL-17A/F, and IL-23) leads simultaneously to accelerated trabecular bone resorption with deterioration of bone microarchitecture and to pathological new bone formation (syndesmophytes, enthesophytes), which locally increases bone mineral density (BMD). As a result, standard dual-energy X-ray absorptiometry (DXA) significantly underestimates the true fracture risk, which is 2-8 times higher than in the general population. The aim of this narrative review was to discuss the pathomechanisms of OP in r-axSpA, with particular emphasis on the role of key pro-inflammatory cytokines, and to critically evaluate the rationale for using antiresorptive, biological, and anabolic therapies in the context of the specific bone pathology of this disease. The review included original research articles, systematic and narrative reviews, and guidelines published between 2015 and 2025, identified through searches in PubMed/MEDLINE, Embase, and Scopus using combinations of keywords related to r-axSpA, osteoporosis, bone microarchitecture (TBS), teriparatide, romosozumab, and inhibitors of TNF-α, IL-17, and JAK. Antiresorptive agents increase BMD but do not interrupt the cytokine-driven catabolic process in trabecular bone, which limits their ability to improve microarchitecture and reduce fracture risk. IL-17A/F inhibitors through effective control of inflammation, exert a beneficial effect on bone metabolism and may slow radiographic progression. Anabolic agents acting primarily via the Wnt/β-catenin pathway, improve not only BMD but, more importantly, bone quality and microarchitecture - making them a potentially more causal treatment option for OP in r-axSpA. Given the dominant role of microarchitectural deterioration, earlier consideration of anabolic agents may be warranted in patients with low trabecular bone score (TBS), abnormal 3D-Shaper results, or low-energy fractures - ideally combined with effective biologic control of inflammation. Prospective clinical trials evaluating this therapeutic strategy are urgently needed.

PMID 43034450
阅读全文 →
PubMedJournal of medicinal chemistry2026-11-12

Development of Long-Acting Teriparatide Analogues through Iterative Peptide Scanning and Site-Specific Modification by Serine/Threonine Ligation.

Liu Biyao B, Song Kaixuan K, Sui Hongli H, Li Zhuang Z et al.

Teriparatide, the only FDA-approved osteoanabolic drug for osteoporosis, suffers from poor metabolic stability and requires frequent subcutaneous injections, leading to suboptimal patient compliance. To find optimized teriparatide derivatives, we herein report an iterative peptide scanning strategy followed by a serine/threonine ligation (STL) chemistry for site-specific modifications. Using our 2-hydroxyphenol-pseudoproline (ψ2-hydroxyphenolpro) modification (HPM) method, two series of teriparatide analogues with different types of substituents were successfully prepared for scanning the modifiable sites and their expansibility. Through chemoselective acylation of embedded serine/threonine residues, several fatty acids of unequal lengths were introduced to further improve the pharmacokinetic properties of scanning derivatives. Among the 12 lipidated analogues, 54, 55, 62, and 63 exhibited potent antiosteoporotic activities in vitro and in vivo close to those of native teriparatide. The most effective compound, 62, also demonstrated significantly enhanced serum stability and may serve as a promising candidate for further development of long-acting antiosteoporotic pharmaceuticals.

PMID 43018567
阅读全文 →
PubMedArchives of osteoporosis2026-11-12

Real-world treatment patterns following denosumab discontinuation: a descriptive epidemiological study.

Yoshiyama Takaki T, Fukasawa Toshiki T, Masuda Soichiro S, Matsuda Shuichi S et al.

This descriptive epidemiological study suggests that sequential osteoporosis therapy after denosumab discontinuation is underutilized in real-world practice. Within 1 year after discontinuation, approximately 30% of patients restarted denosumab, approximately half had no subsequent osteoporosis treatment, and only 16% initiated sequential osteoporosis therapy. To describe real-world treatment patterns following denosumab discontinuation, including delayed reinitiation, no subsequent osteoporosis treatment, and sequential osteoporosis therapy. This descriptive epidemiological study used a Japanese claims database (April 2014-March 2024). We included adults aged ≥40 years who newly initiated denosumab and discontinued it after ≥2 doses. Discontinuation was defined as the last administration before a gap of >240 days or final observed administration followed by ≥240 days without another administration. The primary outcomes within 1 year after discontinuation were delayed denosumab reinitiation, no subsequent osteoporosis treatment, and sequential osteoporosis therapy. We also described the type and timing of sequential therapy and estimated the 1-year cumulative incidence of fragility fractures. Among 37,526 eligible patients, the 1-year cumulative incidence of delayed denosumab reinitiation was 29.6%, the probability of no subsequent osteoporosis treatment was 50.9%, and the cumulative incidence of sequential osteoporosis therapy was 16.3%. Oral bisphosphonates were the most frequently used sequential therapy (26.7%), followed by romosozumab (22.2%), selective estrogen receptor modulators (21.3%), intravenous bisphosphonates (15.1%), teriparatide (14.6%), and abaloparatide (0.1%). Sequential therapy was most often initiated 180-209 days after discontinuation, particularly for romosozumab (45.7%), whereas selective estrogen receptor modulators were frequently initiated 0-29 days after discontinuation (39.8%). The 1-year cumulative incidence of fragility fractures was 5.4%. Within 1 year after discontinuation, approximately 30% of patients restarted denosumab, half received no subsequent osteoporosis treatment, and one in six initiated sequential therapy. These findings suggest a substantial gap in the continuity of osteoporosis care.

PMID 43018839
阅读全文 →
PubMedThe journal of medical investigation : JMI2026-11-11

Effectiveness of switching from once-daily teriparatide to twice-weekly teriparatide:a study of a novel treatment strategy first defined as "teriparatide-switch therapy".

Mineta Kazuaki K, Nishisho Toshihiko T, Okada Masahiko M, Kamada Mitsuhiro M et al.

Once-daily teriparatide (1/d-TPTD) and twice-weekly teriparatide (2/w-TPTD) have high clinical efficacy, but adherence and persistence with treatment remain limited. We introduced a novel strategy involving a transition from 6 months of 1/d-TPTD to 6 months of 2/w-TPTD, which we first defined as "teriparatide-switch therapy" (TST). This study aimed to clarify the effectiveness and safety of TST. The study had a single-arm observational pre-post design and included 38 women with primary osteoporosis. Following 6 months of 1/d-TPTD, they received an additional 6 months of 2/w-TPTD. The incidence of new fractures, safety, and changes in bone mineral density (BMD) and bone turnover markers (BTMs) were recorded. No new fractures occurred during TST. One patient (2.6%) experienced a non-serious adverse event (nausea) after switching to 2/w-TPTD and discontinued treatment. The percent change in BMD was +3.9% at the spine and +0.1% at the total hip at 6 months and +8.2% and +2.2%, respectively, at 12 months. Percent changes in BTMs declined gradually to baseline after switching to 2/w-TPTD. TST was safe and effective in women with treatment-naïve primary osteoporosis. This novel treatment strategy may improve teriparatide continuation rates and help to achieve the treatment goal of fracture prevention. J. Med. Invest. 73 : 419-424, August, 2026.

PMID 43014773
阅读全文 →

注册免费账户还可查看另外 2940 篇文献

免费注册查看全部文献 →

了解更多teriparatide